Trastuzumab Deruxtecan

Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, and a topoisomerase I inhibitor. Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.


Cat. No.: EX-A6996	Purity: >98%

	Chemical structure of Trastuzumab Deruxtecan

For research only, Do not use for Human!

Size	Unit Price (US$)	Stock
100mg	5800	In-stock
250mg	8600	In-stock
500mg	13600	In-stock
1g	get quote	In-stock

Send PO to E-mail:order@excenen.com; or Fax:+86 020 81619670

Discount Request


CAS No.	1826843-81-5
Purity	>98%
Appearance	White to off-white powder
Storage	4℃, Lyophilized Trastuzumab deruxtecan, sealed storage, away from moisture
Shipping	Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Reference:	[1]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518. [2]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46. [3]. Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280.
CoA	CoA of Trastuzumab Deruxtecan


		Search